

Th17 cytokines interleukin (IL)-17 and IL-22 modulate d
keratinocyte-response pathways

British Journal of Dermatology

159, ???-???

DOI: 10.1111/j.1365-2133.2008.08769.x

Citation Report

#	ARTICLE	IF	CITATIONS
2	The International Psoriasis Council Presents Top 2009 Research Articles. Psoriasis Forum, 2009, 15a, 24-32.	0.1	0
3	CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. Journal of Clinical Investigation, 2009, 119, 2317-2329.	8.2	207
4	JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice. Journal of Immunology, 2009, 183, 2183-2192.	0.8	58
5	Human Langerhans cells induce distinct IL-22-producing CD4 ⁺ T cells lacking IL-17 production. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21795-21800.	7.1	227
6	Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Reviews in Molecular Medicine, 2009, 11, e38.	3.9	40
7	Clinical Aspects and Comorbidities of Psoriasis. Journal of rheumatology Supplement, The, 2009, 83, 19-20.	2.2	13
8	Amelioration of Psoriasis by Anti-TNF- α RNAi in the Xenograft Transplantation Model. Molecular Therapy, 2009, 17, 1743-1753.	8.2	67
9	IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. European Journal of Immunology, 2009, 39, 2779-2788.	2.9	95
10	Osteopontin: a new emerging role in psoriasis. Archives of Dermatological Research, 2009, 301, 397-404.	1.9	31
11	A Mutation in the Nlrp3 Gene Causing Inflammasome Hyperactivation Potentiates Th17 Cell-Dominant Immune Responses. Immunity, 2009, 30, 860-874.	14.3	331
12	Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases. Journal of Clinical Immunology, 2009, 29, 247-256.	3.8	90
13	IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN- γ are not. Journal of Molecular Medicine, 2009, 87, 523-536.	3.9	355
15	More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. British Journal of Dermatology, 2009, 161, 1-7.	1.5	116
16	Expression of the Vanin Gene Family in Normal and Inflamed Human Skin: Induction by Proinflammatory Cytokines. Journal of Investigative Dermatology, 2009, 129, 2167-2174.	0.7	68
17	Immunopathogenesis of psoriasis: focus on natural killer T cells. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1123-1127.	2.4	33
18	IL-22-producing α T22 β T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. Journal of Allergy and Clinical Immunology, 2009, 123, 1244-1252.e2.	2.9	547
19	Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. Journal of Allergy and Clinical Immunology, 2009, 124, 1022-1030.e395.	2.9	273
20	The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity, 2009, 42, 574-579.	2.6	52

#	ARTICLE	IF	CITATIONS
21	Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1235-1244.e58.	2.9	231
22	New insights into the pathogenesis and genetics of psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 83-91.	3.2	112
23	Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. <i>Yearbook of Dermatology and Dermatologic Surgery</i> , 2009, 2009, 117-119.	0.0	0
24	In vitro "differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. <i>Blood</i> , 2009, 113, 1365-1374.	1.4	272
25	Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. <i>Blood</i> , 2009, 114, 3101-3112.	1.4	256
26	Psoriasis genetics: breaking the barrier. <i>Trends in Genetics</i> , 2010, 26, 415-423.	6.7	203
27	Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. <i>Virology</i> , 2010, 401, 197-206.	2.4	67
28	Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. <i>European Journal of Immunology</i> , 2010, 40, 2450-2459.	2.9	166
29	IL-17 and IL-22 in atopic allergic disease. <i>Current Opinion in Immunology</i> , 2010, 22, 821-826.	5.5	135
30	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. <i>British Journal of Pharmacology</i> , 2010, 160, 810-820.	5.4	120
31	Primary human keratinocytes efficiently induce IL-17-dependent IL-17 in CCR6+ T cells. <i>Experimental Dermatology</i> , 2010, 19, 1105-1107.	2.9	29
33	British Journal of Dermatology : a fresh complexion. <i>British Journal of Dermatology</i> , 2010, 162, 1-3.	1.5	2
34	Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. <i>British Journal of Dermatology</i> , 2010, 163, 321-328.	1.5	108
35	A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis. <i>British Journal of Dermatology</i> , 2010, 163, 1347-1351.	1.5	22
36	Importance of CD109 and Transforming Growth Factor- β Signaling in Psoriasis. <i>Psoriasis Forum</i> , 2010, 16a, 16-19.	0.1	0
37	Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 123.	2.0	54
38	Current perspectives on the role of IL-17 in autoimmune disease. <i>Journal of Inflammation Research</i> , 2010, 3, 33.	3.5	48
39	Specificity in Killing Pathogens Is Mediated by Distinct Repertoires of Human Neutrophil Peptides. <i>Journal of Innate Immunity</i> , 2010, 2, 508-521.	3.8	28

#	ARTICLE	IF	CITATIONS
40	Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1829-1840.	0.7	192
41	Gene from a Psoriasis Susceptibility Locus Primes the Skin for Inflammation. <i>Science Translational Medicine</i> , 2010, 2, 61ra90.	12.4	66
42	Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis. <i>PLoS ONE</i> , 2010, 5, e14108.	2.5	274
43	IL-24 Transgenic Mice: In Vivo Evidence of Overlapping Functions for IL-20, IL-22, and IL-24 in the Epidermis. <i>Journal of Immunology</i> , 2010, 184, 1793-1798.	0.8	83
44	Redundant and Pathogenic Roles for IL-22 in Mycobacterial, Protozoan, and Helminth Infections. <i>Journal of Immunology</i> , 2010, 184, 4378-4390.	0.8	120
45	A Subpopulation of CD163-Positive Macrophages Is Classically Activated in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2412-2422.	0.7	249
46	IL-1RL2 and Its Ligands Contribute to the Cytokine Network in Psoriasis. <i>Journal of Immunology</i> , 2010, 185, 4354-4362.	0.8	146
47	Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1 β , and TNF- α Recapitulates Some Features of Psoriasis. <i>Journal of Immunology</i> , 2010, 184, 5263-5270.	0.8	274
48	Regulation of the Psoriatic Chemokine CCL20 by E3 Ligases Trim32 and Piasy in Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1384-1390.	0.7	55
49	TGF β 1-Induced Inflammation in Premalignant Epidermal Squamous Lesions Requires IL-17. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2295-2303.	0.7	21
51	CCR6 as a possible therapeutic target in psoriasis. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 911-922.	3.4	51
53	Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA). <i>PLoS ONE</i> , 2010, 5, e10247.	2.5	161
54	Effective Narrow-Band UVB Radiation Therapy Suppresses the IL-23/IL-17 Axis in Normalized Psoriasis Plaques. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2654-2663.	0.7	136
55	Natural killer cells in atopic and autoimmune diseases of the skin. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 60-68.	2.9	81
56	Atopic dermatitis keratinocytes exhibit normal TH17 cytokine responses. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 744-746.e2.	2.9	31
57	IL-17 and IL-22: siblings, not twins. <i>Trends in Immunology</i> , 2010, 31, 354-361.	6.8	206
58	Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. <i>Cytokine</i> , 2010, 49, 163-170.	3.2	44
59	Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 435-441.	7.2	96

#	ARTICLE	IF	CITATIONS
60	IL-17 in cutaneous lupus erythematosus. European Journal of Internal Medicine, 2010, 21, 202-207.	2.2	93
61	New Insights in the Immunologic Basis of Psoriasis. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 3-9.	1.6	162
62	Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2010, 126, 1176-1183.e4.	2.9	93
63	Development of a Bioengineered Skin-Humanized Mouse Model for Psoriasis. American Journal of Pathology, 2010, 177, 3112-3124.	3.8	51
64	Host Defense Mechanisms in Secondary Syphilitic Lesions. American Journal of Pathology, 2010, 177, 2421-2432.	3.8	42
65	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. Journal of Investigative Dermatology, 2010, 130, 1785-1796.	0.7	554
66	Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity, 2010, 43, 215-219.	2.6	72
67	Molecular Dissection of Psoriasis: Integrating Genetics and Biology. Journal of Investigative Dermatology, 2010, 130, 1213-1226.	0.7	253
68	Transcription factor c-Maf mediates the TGF- β -dependent suppression of IL-22 production in TH17 cells. Nature Immunology, 2011, 12, 1238-1245.	14.5	187
69	Distinct Roles of IL-23 and IL-17 in the Development of Psoriasis-Like Lesions in a Mouse Model. Journal of Immunology, 2011, 186, 4481-4489.	0.8	148
70	Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. Journal of Allergy and Clinical Immunology, 2011, 127, 954-964.e4.	2.9	375
71	Contrasting pathogenesis of atopic dermatitis and psoriasis—Part II: Immune cell subsets and therapeutic concepts. Journal of Allergy and Clinical Immunology, 2011, 127, 1420-1432.	2.9	269
72	Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. Journal of Allergy and Clinical Immunology, 2011, 128, 583-593.e4.	2.9	182
73	Histamine modulates the responsiveness of keratinocytes to IL-17 and TNF- α through the H1-receptor. Journal of Dermatological Science, 2011, 61, 79-81.	1.9	9
74	IL-23/TH17 Pathway in Psoriasis and Inflammatory Skin Diseases. , 2011, , 463-480.		1
75	IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A. Journal of Immunology, 2011, 186, 1495-1502.	0.8	212
76	Increased prevalence of TH17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 112, 81-89.	1.4	24
77	Psoriatic Eye Manifestations. Psoriasis Forum, 2011, 17a, 169-179.	0.1	11

#	ARTICLE	IF	CITATIONS
78	Psoriasis Treatments: A Review of the Current Research Pipeline. Psoriasis Forum, 2011, 17a, 11-23.	0.1	4
79	Th17 Cells and Activated Dendritic Cells Are Increased in Vitiligo Lesions. PLoS ONE, 2011, 6, e18907.	2.5	127
81	News from dendritic cells in atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 445-450.	2.3	6
82	Atopic dermatitis - from new pathophysiologic insights to individualized therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 830-839.	5.7	93
83	Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. British Journal of Dermatology, 2011, 164, 344-355.	1.5	53
84	Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. British Journal of Dermatology, 2011, 165, 189-193.	1.5	55
85	Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. British Journal of Dermatology, 2011, 165, 492-498.	1.5	143
86	Phenotypic analysis of perennial airborne allergen-specific CD4 ⁺ T cells in atopic and non-atopic individuals. Clinical and Experimental Allergy, 2011, 41, 1555-1567.	2.9	11
87	Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Experimental Dermatology, 2011, 20, 845-847.	2.9	92
88	Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor. Journal of Investigative Dermatology, 2011, 131, 108-117.	0.7	190
89	Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Annals of the New York Academy of Sciences, 2011, 1222, 30-39.	3.8	51
90	Anti-cytokine therapies for psoriasis. Experimental Cell Research, 2011, 317, 1293-1300.	2.6	51
91	Psoriasis: from pathogenesis to novel therapeutic approaches. Clinical Science, 2011, 120, 1-11.	4.3	83
92	Innate immunity in the pathogenesis of psoriasis. Archives of Dermatological Research, 2011, 303, 691-705.	1.9	81
93	Regulation and function of IL-17A- and IL-22-producing $\gamma\delta$ T cells. Cellular and Molecular Life Sciences, 2011, 68, 2371-2390.	5.4	58
94	IL-22 and TNF- α represent a key cytokine combination for epidermal integrity during infection with <i>Candida albicans</i> . European Journal of Immunology, 2011, 41, 1894-1901.	2.9	122
95	Th1, Th2, Th17 and Regulatory T Cell Pattern in Psoriatic Patients: Modulation of Cytokines and Gene Targets Induced by Etanercept Treatment and Correlation with Clinical Response. Dermatology, 2011, 223, 57-67.	2.1	77
96	IL-21 Promotes Skin Recruitment of CD4 ⁺ Cells and Drives IFN- γ -Dependent Epidermal Hyperplasia. Journal of Immunology, 2011, 186, 5435-5442.	0.8	43

#	ARTICLE	IF	CITATIONS
97	Epidermal CCR6+ $\gamma\delta$ T Cells Are Major Producers of IL-22 and IL-17 in a Murine Model of Psoriasiform Dermatitis. <i>Journal of Immunology</i> , 2011, 187, 5026-5031.	0.8	135
98	Immune Response of Chicken Gut to Natural Colonization by Gut Microflora and to <i>Salmonella enterica</i> Serovar Enteritidis Infection. <i>Infection and Immunity</i> , 2011, 79, 2755-2763.	2.2	265
99	Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 234-242.	4.7	119
100	Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. <i>Journal of Immunology</i> , 2011, 187, 490-500.	0.8	758
101	NK Cells and Psoriasis. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	39
102	Effective Treatment of Psoriasis with Narrow-Band UVB Phototherapy Is Linked to Suppression of the IFN and Th17 Pathways. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1547-1558.	0.7	129
103	Malignant Cutaneous T-Cell Lymphoma Cells Express IL-17 Utilizing the Jak3/Stat3 Signaling Pathway. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1331-1338.	0.7	94
104	IL-23-Mediated Epidermal Hyperplasia Is Dependent on IL-6. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1110-1118.	0.7	68
105	STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. <i>FASEB Journal</i> , 2011, 25, 916-927.	0.5	133
106	Human Papillomavirus Type 8 Interferes with a Novel C/EBP β -Mediated Mechanism of Keratinocyte CCL20 Chemokine Expression and Langerhans Cell Migration. <i>PLoS Pathogens</i> , 2012, 8, e1002833.	4.7	75
107	Human Keratinocytes' Response to Injury Upregulates CCL20 and Other Genes Linking Innate and Adaptive Immunity. <i>Journal of Investigative Dermatology</i> , 2012, 132, 105-113.	0.7	112
108	Biochemical markers of psoriasis as a metabolic disease. <i>Folia Histochemica Et Cytobiologica</i> , 2012, 50, 155-170.	1.5	30
109	Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 423-433.	2.4	111
110	Mechanisms of Rapid Induction of Interleukin-22 in Activated T Cells and Its Modulation by Cyclosporin A. <i>Journal of Biological Chemistry</i> , 2012, 287, 4531-4543.	3.4	18
111	Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2466-2469.	0.7	131
112	IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1 β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. <i>International Immunology</i> , 2012, 24, 147-158.	4.0	120
113	Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis. <i>Journal of Allergy</i> , 2012, 2012, 1-10.	0.7	72
114	Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-5.	3.0	17

#	ARTICLE	IF	CITATIONS
115	The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. International Journal of Rheumatology, 2012, 2012, 1-8.	1.6	41
116	In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection. Future Virology, 2012, 7, 719-728.	1.8	3
117	Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 130, 1344-1354.	2.9	731
118	Current investigational drugs in psoriasis. Expert Opinion on Investigational Drugs, 2012, 21, 473-487.	4.1	33
119	Psoriasis drug discovery: methods for evaluation of potential drug candidates. Expert Opinion on Drug Discovery, 2012, 7, 49-61.	5.0	13
120	Regulating with Reg Proteins: A New Role in Th17 Cell-Mediated Skin inflammation. Immunity, 2012, 37, 5-7.	14.3	4
121	Targeting the Th17 pathway in psoriasis. Journal of Leukocyte Biology, 2012, 92, 1187-1197.	3.3	84
122	Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Human Immunology, 2012, 73, 629-635.	2.4	68
123	The promotional effect of IL-22 on mineralization activity of periodontal ligament cells. Cytokine, 2012, 59, 41-48.	3.2	32
124	Psoriasis: rationale for targeting interleukin-17. British Journal of Dermatology, 2012, 167, 717-724.	1.5	120
125	New insights of T cells in the pathogenesis of psoriasis. Cellular and Molecular Immunology, 2012, 9, 302-309.	10.5	290
126	An update on the role of human dendritic cells in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 129, 879-886.	2.9	68
127	Mechanisms of IFN- γ -induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2012, 129, 1297-1306.	2.9	128
128	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. Journal of Allergy and Clinical Immunology, 2012, 130, 145-154.e9.	2.9	320
129	Keratin 17 as a therapeutic target for the treatment of psoriasis. Journal of Dermatological Science, 2012, 67, 161-165.	1.9	38
130	Analysis of genetic variants of class II cytokine and their receptor genes in psoriasis patients of two ethnic groups from the Volga-Ural region of Russia. Journal of Dermatological Science, 2012, 68, 9-18.	1.9	9
131	Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis. Journal of Investigative Dermatology, 2012, 132, 2552-2564.	0.7	240
132	Post-Therapeutic Relapse of Psoriasis after CD11a Blockade Is Associated with T Cells and Inflammatory Myeloid DCs. PLoS ONE, 2012, 7, e30308.	2.5	29

#	ARTICLE	IF	CITATIONS
133	Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease. PLoS ONE, 2012, 7, e44274.	2.5	149
134	Humanized Mouse Model of Skin Inflammation Is Characterized by Disturbed Keratinocyte Differentiation and Influx of IL-17A Producing T Cells. PLoS ONE, 2012, 7, e45509.	2.5	17
135	Differential Capacity of Human Skin Dendritic Cells to Polarize CD4 ⁺ T Cells into IL-17, IL-21 and IL-22 Producing Cells. PLoS ONE, 2012, 7, e45680.	2.5	32
137	The Therapeutic Applications of Janus Kinase Inhibition in Psoriasis. Psoriasis Forum, 2012, 18a, 118-125.	0.1	0
138	Pathogenesis of Psoriasis: The Role of Pro-Inflammatory Cytokines Produced by Keratinocytes. , 0, , .		8
139	Effect of Spa Spring Water on Cytokine Expression in Human Keratinocyte HaCaT Cells and on Differentiation of CD4 ⁺ T Cells. Annals of Dermatology, 2012, 24, 324.	0.9	24
140	Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. European Journal of Immunology, 2012, 42, 901-911.	2.9	26
142	The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 3-11.	2.4	253
143	Increased frequencies of IL-13 ⁺ producing T cells are found in chronic atopic dermatitis skin. Experimental Dermatology, 2012, 21, 431-436.	2.9	107
144	Critical role of the interleukin-23/Thelper 17 cell axis in the pathogenesis of psoriasis. Journal of Dermatology, 2012, 39, 219-224.	1.2	44
145	Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. British Journal of Dermatology, 2012, 167, 92-102.	1.5	40
146	Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 242-250.	2.4	55
147	The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. Journal of Investigative Dermatology, 2013, 133, 17-26.	0.7	369
148	Induction and exacerbation of psoriasis with Interferon-α therapy for hepatitis C: A review and analysis of 36 cases. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 771-778.	2.4	65
149	IL-17 and TNF Synergistically Modulate Cytokine Expression while Suppressing Melanogenesis: Potential Relevance to Psoriasis. Journal of Investigative Dermatology, 2013, 133, 2741-2752.	0.7	156
150	Burden of Disease: Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2013, 14, 377-388.	6.7	118
151	The role of IL-22 and Th22 cells in human skin diseases. Journal of Dermatological Science, 2013, 72, 3-8.	1.9	147
152	Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. Clinical Reviews in Allergy and Immunology, 2013, 44, 121-140.	6.5	69

#	ARTICLE	IF	CITATIONS
153	Cytokine-Based Therapy in Psoriasis. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 173-182.	6.5	48
154	Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 300-313.	2.9	185
155	Expression of microRNA-184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013, 228, 2314-2323.	4.1	39
156	IL-22 in tissue-protective therapy. <i>British Journal of Pharmacology</i> , 2013, 169, 761-771.	5.4	60
157	IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities. <i>Cytokine</i> , 2013, 62, 195-201.	3.2	76
158	Th17 cells and IL-17: Focus on immunopathogenesis and immunotherapeutics. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 158-170.	3.4	125
159	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013, 15, R136.	3.5	212
160	Chemokine receptors in psoriasis. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1405-1422.	3.4	17
161	Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response. <i>British Journal of Dermatology</i> , 2013, 168, 990-998.	1.5	11
162	Long-term safety of ustekinumab for psoriasis. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 757-765.	2.4	10
163	Essentials of Th17 cell commitment and plasticity. <i>Blood</i> , 2013, 121, 2402-2414.	1.4	306
164	The IL-23/Th17 pathogenic axis in psoriasis is amplified by keratinocyte responses. <i>Trends in Immunology</i> , 2013, 34, 174-181.	6.8	399
165	The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs, and Skin. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 477-512.	22.4	384
166	Streptococcus Induces Circulating CLA+ Memory T-Cell-Dependent Epidermal Cell Activation in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 999-1007.	0.7	35
167	Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 361-370.	2.9	402
168	Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 498-501.e3.	2.9	39
169	IL-27 suppresses the production of IL-22 in human CD4+ T cells by inducing the expression of SOCS1. <i>Immunology Letters</i> , 2013, 152, 96-103.	2.5	21
170	Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1094-1102.	2.9	212

#	ARTICLE	IF	CITATIONS
171	Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation. <i>Journal of Immunology</i> , 2013, 190, 2252-2262.	0.8	260
172	The Th17 Pathway as a Therapeutic Target in Rheumatoid Arthritis and Other Autoimmune and Inflammatory Disorders. <i>BioDrugs</i> , 2013, 27, 439-452.	4.6	24
174	Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model. <i>Archives of Dermatological Research</i> , 2013, 305, 501-512.	1.9	35
175	<i>Integument.</i> , 2013, , 2219-2275.		4
176	Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and ROR γ t-positive IL-17 producing T-cell populations. <i>Journal of Dermatological Science</i> , 2013, 69, 44-53.	1.9	21
177	Norepinephrine and adenosine-5â€²-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells. <i>Cytokine</i> , 2013, 64, 605-612.	3.2	32
178	An Alternative Pathway of Imiquimod-Induced Psoriasis-Like Skin Inflammation in the Absence of Interleukin-17 Receptor A Signaling. <i>Journal of Investigative Dermatology</i> , 2013, 133, 441-451.	0.7	143
179	Systemically Elevated Th1-, Th2- and Th17-associated Chemokines in Psoriasis Vulgaris Before and After Ultraviolet B Treatment. <i>Acta Dermato-Venereologica</i> , 2013, 93, 527-531.	1.3	25
180	Rationale and early clinical data on IL-17 blockade in psoriasis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 677-682.	3.0	10
181	Immunotargeting in the management of psoriasis. <i>ImmunoTargets and Therapy</i> , 2013, 2, 51.	5.8	2
182	Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons?. <i>Frontiers in Immunology</i> , 2013, 4, 18.	4.8	69
183	Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. <i>Core Evidence</i> , 2014, 9, 89.	4.7	21
184	IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. <i>PLoS ONE</i> , 2014, 9, e90284.	2.5	149
185	Interleucina-17 como Alvo Terapêutico na Psoríase. <i>Acta Medica Portuguesa</i> , 2014, 27, 252-258.	0.4	7
187	Three-Dimensional Skin Models of Psoriasis. <i>Cells Tissues Organs</i> , 2014, 199, 301-310.	2.3	7
188	Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis. <i>Journal of Immunology</i> , 2014, 192, 3111-3120.	0.8	305
189	Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 523-532.	0.6	24
190	Cytokine Effects Induced by the Human Autoallergen Î±-NAC. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1570-1578.	0.7	29

#	ARTICLE	IF	CITATIONS
191	The immunological and genetic aspects in psoriasis. Applied Informatics, 2014, 1, .	0.5	6
192	Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	20
193	Regulatory Networks Contributing to Psoriasis Susceptibility. Acta Dermato-Venereologica, 2014, 94, 380-385.	1.3	24
194	Dominant Th1 and Minimal Th17 Skewing in Discoid Lupus Revealed by Transcriptomic Comparison with Psoriasis. Journal of Investigative Dermatology, 2014, 134, 87-95.	0.7	95
195	Current Concepts in Psoriatic Arthritis: Pathogenesis and Management. Acta Dermato-Venereologica, 2014, 94, 627-634.	1.3	58
196	Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. Journal of Experimental Medicine, 2014, 211, 499-513.	8.5	93
197	Recent advances in epidemiology and prevention of atopic eczema. Pediatric Allergy and Immunology, 2014, 25, 630-638.	2.6	27
198	Shared decision making in dermatology: asking patients, "What is important to you?". British Journal of Dermatology, 2014, 170, 759-760.	1.5	13
199	Apremilast for the treatment of psoriatic arthritis. Expert Review of Clinical Pharmacology, 2014, 7, 239-250.	3.1	11
200	The Biology and Functions of Th22 Cells. Advances in Experimental Medicine and Biology, 2014, 841, 209-230.	1.6	97
201	IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	72
202	Targeting Interleukin-22 in Psoriasis. Inflammation, 2014, 37, 94-99.	3.8	87
203	Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal of Allergy and Clinical Immunology, 2014, 133, 1626-1634.	2.9	146
204	Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology, 2014, 141, 133-142.	4.4	200
205	Immunology of Psoriasis. Annual Review of Immunology, 2014, 32, 227-255.	21.8	1,242
206	Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression. Arthritis and Rheumatology, 2014, 66, 1272-1281.	5.6	226
207	Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody. Journal of Immunology, 2014, 192, 3828-3836.	0.8	130
208	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Journal of the American Academy of Dermatology, 2014, 71, 141-150.	1.2	267

#	ARTICLE	IF	CITATIONS
209	The IL-23/IL-17 axis in psoriatic arthritis. <i>Autoimmunity Reviews</i> , 2014, 13, 496-502.	5.8	132
210	Inositol-C2-PAF down-regulates components of the antigen presentation machinery in a 2D-model of epidermal inflammation. <i>Biochemical Pharmacology</i> , 2014, 87, 477-488.	4.4	10
211	Increased prevalence of psoriasis in patients with coronary artery disease: results from a case-control study. <i>British Journal of Dermatology</i> , 2014, 171, 580-587.	1.5	15
212	Egr-1 is a key regulator of IL-17A-induced psoriasin upregulation in psoriasis. <i>Experimental Dermatology</i> , 2014, 23, 890-895.	2.9	20
213	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. <i>Autoimmunity</i> , 2014, 47, 287-306.	2.6	16
214	Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. <i>Nanomedicine</i> , 2014, 9, 2157-2174.	3.3	49
215	The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2898-2907.	0.7	133
216	An increased proportion of circulating Th22 and Tc22 cells in psoriasis. <i>Cellular Immunology</i> , 2014, 290, 196-200.	3.0	30
217	IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2757-2767.	0.7	121
218	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014, 14, 47-53.	1.9	7
219	IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing $\gamma\delta$ T Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1912-1921.	0.7	142
220	Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 769-779.	2.9	375
221	The Antiangiogenic Insulin Receptor Substrate-1 Antisense Oligonucleotide Aganirsen Impairs AU-Rich mRNA Stability by Reducing 14-3-3 η -Tristetraprolin Protein Complex, Reducing Inflammation and Psoriatic Lesion Size in Patients. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 107-117.	2.5	11
222	Interleukin 17A Promotes Pneumococcal Clearance by Recruiting Neutrophils and Inducing Apoptosis through a p38 Mitogen-Activated Protein Kinase-Dependent Mechanism in Acute Otitis Media. <i>Infection and Immunity</i> , 2014, 82, 2368-2377.	2.2	35
223	Molecular Biology of Atopic Dermatitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2014, 47, 193-218.	6.5	76
224	The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. <i>Autoimmunity Highlights</i> , 2014, 5, 9-19.	3.9	83
225	The Role of Interleukin-17A in Psoriatic Disease. <i>BioDrugs</i> , 2014, 28, 487-497.	4.6	37
226	MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 836-847.e11.	2.9	152

#	ARTICLE	IF	CITATIONS
227	Th17 cells in inflammation and autoimmunity. Autoimmunity Reviews, 2014, 13, 1174-1181.	5.8	182
228	Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3669-78.	7.1	121
229	DNAX-activating Protein 10 (DAP10) Membrane Adaptor Associates with Receptor for Advanced Glycation End Products (RAGE) and Modulates the RAGE-triggered Signaling Pathway in Human Keratinocytes. Journal of Biological Chemistry, 2014, 289, 23389-23402.	3.4	34
230	Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 371-379.	3.8	136
231	The role of the IL-22/IL-22R1 axis in cancer. Cytokine and Growth Factor Reviews, 2014, 25, 257-271.	7.2	141
232	NK Cell Autoreactivity and Autoimmune Diseases. Frontiers in Immunology, 2014, 5, 27.	4.8	77
233	New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatologic Therapy, 2015, 28, 179-193.	1.7	49
234	Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Experimental Dermatology, 2015, 24, 529-535.	2.9	157
235	T-helper 22 cells as a new player in chronic inflammatory skin disorders. International Journal of Dermatology, 2015, 54, 880-888.	1.0	33
236	Effect of Pregnancy on Psoriasis and Psoriatic Arthritis. Psoriasis Forum, 2015, 21a, 12-27.	0.1	0
237	Clinical potential of brodalumab in the management of psoriasis: the evidence to date. Psoriasis: Targets and Therapy, 2015, 5, 35.	2.2	0
238	Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. Journal of Clinical Medicine, 2015, 4, 858-873.	2.4	100
239	MR1-Restricted Mucosal-Associated Invariant T Cells and Their Activation during Infectious Diseases. Frontiers in Immunology, 2015, 6, 303.	4.8	66
240	KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome. PLoS Genetics, 2015, 11, e1005389.	3.5	73
241	IL-22/STAT3-Induced Increases in SLURP1 Expression within Psoriatic Lesions Exerts Antimicrobial Effects against Staphylococcus aureus. PLoS ONE, 2015, 10, e0140750.	2.5	20
242	A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. PLoS ONE, 2015, 10, e0142081.	2.5	69
243	Defects of corneocyte structural proteins and epidermal barrier in atopic dermatitis. Biological Chemistry, 2015, 396, 1163-1179.	2.5	24
244	Targeting IL-17 with ixekizumab in patients with psoriasis. Immunotherapy, 2015, 7, 957-966.	2.0	6

#	ARTICLE	IF	CITATIONS
245	New pathogenic and therapeutic paradigms in atopic dermatitis. <i>Cytokine</i> , 2015, 73, 311-318.	3.2	95
246	The translational revolution and use of biologics in patients with inflammatory skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 324-336.	2.9	175
247	Tear functions in patients with vitiligo. <i>International Journal of Dermatology</i> , 2015, 54, e466-8.	1.0	7
248	Ixekizumab for treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 435-442.	3.0	9
249	Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2015, 17, 55.	4.7	42
250	Galectin-3 in autoimmunity and autoimmune diseases. <i>Experimental Biology and Medicine</i> , 2015, 240, 1019-1028.	2.4	120
251	Investigation of anti-inflammatory and anti-proliferative activities promoted by photoactivated cationic porphyrin. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 444-458.	2.6	13
252	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. <i>American Journal of Medicine</i> , 2015, 128, 1325-1334.e2.	1.5	94
253	Dual Inhibition of Interleukin-23 and Interleukin-17 Offers Superior Efficacy in Mouse Models of Autoimmunity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 152-165.	2.5	20
255	Th22 cells in allergic disease. <i>Allergo Journal International</i> , 2015, 24, 1-7.	2.0	40
256	IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 210-220.	1.4	2
257	Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. <i>Immunotherapy</i> , 2015, 7, 323-333.	2.0	10
258	IL-17A, IL-22, and IL-23 as Markers of Psoriasis Activity. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 555-560.	1.2	38
259	Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1019-1023.	2.2	57
260	Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. <i>JAMA Dermatology</i> , 2015, 151, 753.	4.1	72
261	The genomic landscape of human immune-mediated diseases. <i>Journal of Human Genetics</i> , 2015, 60, 675-681.	2.3	19
262	Biological therapy induces expression changes in Notch pathway in psoriasis. <i>Archives of Dermatological Research</i> , 2015, 307, 863-873.	1.9	14
263	A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. <i>Journal of Experimental Medicine</i> , 2015, 212, 1571-1587.	8.5	170

#	ARTICLE	IF	CITATIONS
264	Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 934-944.	5.6	94
265	Syk Mediates IL-17-Induced CCL20 Expression by Targeting Act1-Dependent K63-Linked Ubiquitination of TRAF6. <i>Journal of Investigative Dermatology</i> , 2015, 135, 490-498.	0.7	54
266	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). <i>British Journal of Dermatology</i> , 2015, 172, 484-493.	1.5	279
267	The Immunopathogenesis of Psoriasis. <i>Dermatologic Clinics</i> , 2015, 33, 13-23.	1.7	269
268	Recent advances in understanding psoriasis. <i>F1000Research</i> , 2016, 5, 770.	1.6	105
269	T Helper Cell Subsets in Clinical Manifestations of Psoriasis. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	2.2	82
270	Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 244.	4.1	13
271	Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 148.	4.8	26
272	Development of a Topical Treatment for Psoriasis Targeting ROR γ : From Bench to Skin. <i>PLoS ONE</i> , 2016, 11, e0147979.	2.5	66
273	Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0148450.	2.5	33
274	Current knowledge on psoriasis and autoimmune diseases. <i>Psoriasis: Targets and Therapy</i> , 2016, 6, 7.	2.2	122
275	Erythrodermic psoriasis: pathophysiology and current treatment perspectives. <i>Psoriasis: Targets and Therapy</i> , 2016, Volume 6, 93-104.	2.2	52
276	The crucial role of IL-22 and its receptor in thymus and activation regulated chemokine production and T-cell migration by house dust mite extract. <i>Experimental Dermatology</i> , 2016, 25, 598-603.	2.9	18
277	Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report. <i>Cytokine</i> , 2016, 85, 130-136.	3.2	26
278	Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). <i>Journal of Controlled Release</i> , 2016, 239, 182-202.	9.9	77
279	Cytokines IL-17 and IL-22 in the host response to infection. <i>Pathogens and Disease</i> , 2016, 74, ftw111.	2.0	138
280	Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. <i>Scientific Reports</i> , 2016, 6, 19295.	3.3	48
281	The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 509-516.	1.2	27

#	ARTICLE	IF	CITATIONS
282	New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis. <i>Autoimmunity</i> , 2016, 49, 435-450.	2.6	84
283	Skin Immunity to <i>Candida albicans</i> . <i>Trends in Immunology</i> , 2016, 37, 440-450.	6.8	107
284	IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory disease. <i>Immunology Letters</i> , 2016, 178, 20-26.	2.5	115
285	MCPIP1 RNase Is Aberrantly Distributed in Psoriatic Epidermis and Rapidly Induced by IL-17A. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1599-1607.	0.7	38
286	Keratinocytes contribute intrinsically to psoriasis upon loss of <i>Tnfr1</i> function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6162-E6171.	7.1	62
287	A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1337-1344.	4.1	13
288	Psoriasis-like lesions in a patient with familial Mediterranean fever. <i>Journal of Dermatology</i> , 2016, 43, 314-317.	1.2	8
289	Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. <i>Rheumatology</i> , 2016, 55, ii43-ii55.	1.9	50
290	A PPAR γ -selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice. <i>International Immunopharmacology</i> , 2016, 40, 73-78.	3.8	9
291	Host-Bacterial Crosstalk Determines <i>Staphylococcus aureus</i> Nasal Colonization. <i>Trends in Microbiology</i> , 2016, 24, 872-886.	7.7	79
292	Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris. <i>International Journal of Dermatology</i> , 2016, 55, 1242-1247.	1.0	15
293	Secukinumab: a promising therapeutic option in spondyloarthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2151-2161.	2.2	2
294	Human IL-22 binding protein isoforms act as a rheostat for IL-22 signaling. <i>Science Signaling</i> , 2016, 9, ra95.	3.6	27
295	Asymmetric stem-cell division ensures sustained keratinocyte hyperproliferation in psoriatic skin lesions. <i>International Journal of Molecular Medicine</i> , 2016, 37, 359-368.	4.0	33
296	Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. <i>Experimental Cell Research</i> , 2016, 345, 247-254.	2.6	17
297	Genetic Basis of Irritant Susceptibility in Health Care Workers. <i>Journal of Occupational and Environmental Medicine</i> , 2016, 58, 753-759.	1.7	8
298	The many faces of interleukin-17 in inflammatory skin diseases. <i>British Journal of Dermatology</i> , 2016, 175, 892-901.	1.5	75
299	Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. <i>Experimental Dermatology</i> , 2016, 25, 453-459.	2.9	63

#	ARTICLE	IF	CITATIONS
300	Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 51, 87-99.	6.5	31
301	Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab. <i>JAMA Dermatology</i> , 2016, 152, 482.	4.1	32
302	Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. <i>Molecular and Cellular Biochemistry</i> , 2016, 415, 1-11.	3.1	30
303	<i>In Vitro</i> Skin Models and Their Predictability in Defining Normal and Disease Biology, Pharmacology, and Toxicity. <i>Toxicologic Pathology</i> , 2016, 44, 555-563.	1.8	30
304	An Overview of the Pathogenesis of Immune-mediated Skin Injury. <i>Toxicologic Pathology</i> , 2016, 44, 536-544.	1.8	7
305	Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control <i>Staphylococcus aureus</i> colonization of the nasal mucosa. <i>Mucosal Immunology</i> , 2016, 9, 1429-1441.	6.0	49
306	Interferon- γ Protects from Staphylococcal Alpha Toxin-Induced Keratinocyte Death through Apolipoprotein L1. <i>Journal of Investigative Dermatology</i> , 2016, 136, 658-664.	0.7	9
307	Cytokine Pathways in Psoriasis and Psoriatic Arthritis. , 2016, , 73-82.		4
308	IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IL-1 β in keratinocytes. <i>International Immunology</i> , 2016, 28, 443-452.	4.0	59
309	Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1153-1164.	3.3	52
310	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 255-263.	3.1	18
311	Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1091-1102.e7.	2.9	126
312	Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF- κ B and proinflammatory cytokines. <i>Journal of Molecular Medicine</i> , 2016, 94, 195-206.	3.9	35
313	Treatment of Eczema: Corticosteroids and Beyond. <i>Clinical Reviews in Allergy and Immunology</i> , 2016, 51, 249-262.	6.5	43
314	Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. <i>Allergology International</i> , 2017, 66, 398-403.	3.3	202
315	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 305-314.	0.4	14
316	Safety evaluation of apremilast for the treatment of psoriasis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 381-385.	2.4	20
317	Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon- γ Antibody, in Patients With Discoid Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1028-1034.	5.6	62

#	ARTICLE	IF	CITATIONS
318	Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 876-885.	2.0	48
319	Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1501-1511.	0.7	22
320	The role of IL 23 in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 525-534.	3.0	111
321	The role of IL-17 in the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 815-821.	3.0	10
322	Cytokines and Chemokines. , 2017, , 239-264.		0
323	Systemic Therapy of Atopic Dermatitis: When, How, for How Long?. <i>Current Dermatology Reports</i> , 2017, 6, 149-160.	2.1	0
324	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2017, 108, 305-314.	0.4	2
325	Skin-infiltrating, interleukin-22â€producing T cells differentiate pediatric psoriasis from adult psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 417-424.	1.2	37
326	Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1184-1187.e8.	2.9	4
327	<i>InÂvitro</i> psoriasis models with focus on reconstructed skin models as promising tools in psoriasis research. <i>Experimental Biology and Medicine</i> , 2017, 242, 1158-1169.	2.4	44
328	Tapinarof Is a Natural AhR Agonist thatÂResolves Skin Inflammation in MiceÂandÂHumans. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2110-2119.	0.7	236
329	An Update on the Pathophysiology of Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2017, 35, 317-326.	1.7	88
330	Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1723-1734.	2.9	202
331	Cyr61/CCN1 induces CCL20 production by keratinocyte via activating p38 and JNK/AP-1 pathway in psoriasis. <i>Journal of Dermatological Science</i> , 2017, 88, 46-56.	1.9	22
332	Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin. <i>British Journal of Dermatology</i> , 2017, 177, e321-e322.	1.5	40
333	The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, S65-S76.	2.9	453
334	Serum peptides as putative modulators of inflammation in psoriasis. <i>Journal of Dermatological Science</i> , 2017, 87, 36-49.	1.9	12
335	Systemic therapies in atopic dermatitis: The pipeline. <i>Clinics in Dermatology</i> , 2017, 35, 387-397.	1.6	23

#	ARTICLE	IF	CITATIONS
336	MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation. <i>Journal of Immunology</i> , 2017, 198, 767-775.	0.8	65
337	ACKR2: Nature's™ Decoy Receptor Lures Unsuspecting Chemokines in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 7-11.	0.7	7
338	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 2S-40S.	1.2	9
339	P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17. <i>Molecular Medicine Reports</i> , 2017, 16, 8863-8867.	2.4	48
340	AKT2 is involved in the IL-17A-mediated promotion of differentiation and calcification of murine preosteoblastic MC3T3-E1 cells. <i>Molecular Medicine Reports</i> , 2017, 16, 5833-5840.	2.4	6
341	An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	124
342	Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. <i>Current Opinion in Immunology</i> , 2017, 48, 68-73.	5.5	258
343	Quercitrin extracted from Tartary buckwheat alleviates imiquimod-induced psoriasis-like dermatitis in mice by inhibiting the Th17 cell response. <i>Journal of Functional Foods</i> , 2017, 38, 9-19.	3.4	12
344	Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1999-2009.	2.4	150
345	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. <i>Dermatology and Therapy</i> , 2017, 7, 265-279.	3.0	31
346	Editor's™ Highlight: Ah Receptor Activation Potentiates Neutrophil Chemoattractant (C-X-C Motif) Ligand 5 Expression in Keratinocytes and Skin. <i>Toxicological Sciences</i> , 2017, 160, 83-94.	3.1	25
347	The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. <i>Scientific Reports</i> , 2017, 7, 15631.	3.3	94
348	Emerging Associations Between Neutrophils, Atherosclerosis, and Psoriasis. <i>Current Atherosclerosis Reports</i> , 2017, 19, 53.	4.8	27
350	Protective role of IL-22 against <i>Schistosoma mansoni</i> soluble egg antigen-induced granuloma in Vitro. <i>Parasite Immunology</i> , 2017, 39, e12392.	1.5	10
351	Allergies – A T cells perspective in the era beyond the TH1/TH2 paradigm. <i>Clinical Immunology</i> , 2017, 174, 73-83.	3.2	47
352	An IL-17- dominant immune profile is shared across the major orphan forms of ichthyosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 152-165.	2.9	135
353	Sexy again: the renaissance of neutrophils in psoriasis. <i>Experimental Dermatology</i> , 2017, 26, 305-311.	2.9	71
354	Stem cells in psoriasis. <i>Journal of Dermatological Science</i> , 2017, 86, 181-186.	1.9	19

#	ARTICLE	IF	CITATIONS
355	Interleukin-17 A-E. , 2017, , 549-572.		2
356	Psoriasis and Other Skin Inflammatory Diseases. , 2017, , 1091-1104.		1
357	Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies. Dermatology, 2017, 233, 344-357.	2.1	50
358	Human Translational Research in Psoriasis Using CLA+ T Cells. , 2017, , .		0
359	East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis. Frontiers in Pharmacology, 2017, 8, 125.	3.5	30
360	Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives. Psoriasis: Targets and Therapy, 2017, Volume 7, 73-85.	2.2	8
361	Models in the Research Process of Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2514.	4.1	82
362	A Human Lin ⁺ CD123+ CD127 ^{low} Population Endowed with ILC Features and Migratory Capabilities Contributes to Immunopathological Hallmarks of Psoriasis. Frontiers in Immunology, 2017, 8, 176.	4.8	15
363	Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF Therapy. Frontiers in Immunology, 2017, 8, 932.	4.8	25
364	Contribution of <i>In Vivo</i> and Organotypic 3D Models to Understanding the Role of Macrophages and Neutrophils in the Pathogenesis of Psoriasis. Mediators of Inflammation, 2017, 2017, 1-13.	3.0	23
365	The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators of Inflammation, 2017, 2017, 1-11.	3.0	328
366	Therapeutic Effects of Methanol Extract from <i>Euphorbia kansui</i> Radix on Imiquimod-Induced Psoriasis. Journal of Immunology Research, 2017, 2017, 1-17.	2.2	16
367	Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis. , 0, , .		6
368	Interleukin-22 participates in the inflammatory process of vitiligo. Oncotarget, 2017, 8, 109161-109174.	1.8	11
369	Immunosuppressants for the Treatment of Psoriasis. Journal of the Nihon University Medical Association, 2017, 76, 31-35.	0.0	0
370	A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy, 2018, 10, 361-372.	2.0	15
371	Psoriatic arthritis: tissue-directed inflammation?. Clinical Rheumatology, 2018, 37, 859-868.	2.2	21
372	Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome. Journal of Investigative Dermatology, 2018, 138, 1754-1763.	0.7	82

#	ARTICLE	IF	CITATIONS
373	Past, present and future of in vitro 3D reconstructed inflammatory skin models to study psoriasis. <i>Experimental Dermatology</i> , 2018, 27, 512-519.	2.9	22
374	An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation. <i>Immunity</i> , 2018, 48, 787-798.e4.	14.3	97
375	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 872-881.e6.	1.2	265
376	Increased risk of psoriasis following scabies infection: A nationwide population-based matched-cohort study. <i>Journal of Dermatology</i> , 2018, 45, 302-308.	1.2	7
377	PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1795-1803.	3.8	96
378	Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 5-21.	2.5	121
379	Autoimmunity and autoimmune co-morbidities in psoriasis. <i>Immunology</i> , 2018, 154, 21-27.	4.4	49
380	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. <i>Cellular and Molecular Immunology</i> , 2018, 15, 458-469.	10.5	331
381	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Experimental Dermatology</i> , 2018, 27, 409-417.	2.9	143
382	Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028522.	5.5	226
383	Review of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 347-352.	2.2	21
384	STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC. <i>Journal of Investigative Dermatology</i> , 2018, 138, 711-714.	0.7	29
385	MiR-548a-3p Promotes Keratinocyte Proliferation Targeting PPP3R1 after Being Induced by IL-22. <i>Inflammation</i> , 2018, 41, 496-504.	3.8	20
386	Characterization of CD 45 RO + memory T lymphocytes in keloid disease. <i>British Journal of Dermatology</i> , 2018, 178, 940-950.	1.5	34
387	Cytokine Network. , 2018, , 97-112.		1
388	Role of chemokines and the corresponding receptors in vitiligo: A pilot study. <i>Journal of Dermatology</i> , 2018, 45, 31-38.	1.2	27
389	Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF- α /IFN- γ -induced inflammatory response in keratinocytes and T cell-derived IL-17. <i>Pharmacological Research</i> , 2018, 129, 443-452.	7.1	43
390	Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. <i>Experimental Dermatology</i> , 2018, 27, 115-123.	2.9	97

#	ARTICLE	IF	CITATIONS
391	Immunologic, microbial, and epithelial interactions in atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 34-41.	1.0	120
392	Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 295-311.	6.5	57
393	Systematic screening and identification of novel psoriasis-specific genes from the transcriptome of psoriasis-like keratinocytes. <i>Molecular Medicine Reports</i> , 2018, 19, 1529-1542.	2.4	7
395	MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. <i>Journal of Clinical Investigation</i> , 2018, 128, 2551-2568.	8.2	182
396	Tetrandrine inhibits the proliferation and cytokine production induced by IL-22 in HaCaT cells. <i>Journal of International Medical Research</i> , 2018, 46, 5210-5218.	1.0	5
397	Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. <i>PLoS ONE</i> , 2018, 13, e0203672.	2.5	71
398	Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab. <i>JAAD Case Reports</i> , 2018, 4, 842-844.	0.8	2
399	The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. <i>Experimental Dermatology</i> , 2019, 28, 3-10.	2.9	51
400	5-Hydroxytryptophan attenuates imiquimod-induced psoriasisiform dermatitis probably through inhibition of IL-17A production and keratinocyte activation. <i>Experimental Dermatology</i> , 2018, 27, 1273-1279.	2.9	6
401	Differential efficacy of biologic treatments targeting the TNF- α /IL-23/IL-17 axis in psoriasis and psoriatic arthritis. <i>Cytokine</i> , 2018, 111, 182-188.	3.2	60
402	Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 727-735.	3.1	52
403	STAT1 activation represses IL-22 gene expression and psoriasis pathogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 563-569.	2.1	20
404	Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis. <i>International Immunopharmacology</i> , 2018, 61, 74-81.	3.8	49
405	Generalized pustular psoriasis – a model disease for specific targeted immunotherapy, systematic review. <i>Experimental Dermatology</i> , 2018, 27, 1067-1077.	2.9	56
406	Notch1 Signaling Regulates the Th17/Treg Immune Imbalance in Patients with Psoriasis Vulgaris. <i>Mediators of Inflammation</i> , 2018, 2018, 1-10.	3.0	40
407	Nobiletin and 5-Hydroxy-6,7,8,3a,4a-pentamethoxyflavone Ameliorate 12-O-Tetradecanoylphorbol-13-acetate-Induced Psoriasis-Like Mouse Skin Lesions by Regulating the Expression of Ki-67 and Proliferating Cell Nuclear Antigen and the Differentiation of CD4 ⁺ T Cells through Mitogen-Activated Protein Kinase Signaling Pathways. <i>Journal of Agricultural and Food Chemistry</i> , 2018, 66, 8299-8306.	5.2	27
408	IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo. <i>FASEB Journal</i> , 2018, 32, 4899-4916.	0.5	57
409	East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease. <i>Frontiers in Pharmacology</i> , 2018, 9, 200.	3.5	15

#	ARTICLE	IF	CITATIONS
410	The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. <i>Frontiers in Immunology</i> , 2018, 9, 1549.	4.8	279
411	Relapsing Polychondritis following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2018, 2018, 1-4.	0.6	5
412	Immunotopographical Differences of Human Skin. <i>Frontiers in Immunology</i> , 2018, 9, 424.	4.8	32
413	MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease. <i>Frontiers in Immunology</i> , 2018, 9, 569.	4.8	15
414	Scanning the Immunopathogenesis of Psoriasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 179.	4.1	212
415	Protein biomarker for psoriasis: A systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis. <i>International Journal of Biological Macromolecules</i> , 2018, 118, 1796-1810.	7.5	34
416	Development of psoriasis by continuous neutrophil infiltration into the epidermis. <i>Experimental Dermatology</i> , 2018, 27, 1084-1091.	2.9	54
417	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.5	57
418	Dang-Gui-Liu-Huang Tang a traditional herbal formula, ameliorates imiquimod-induced psoriasis-like skin inflammation in mice by inhibiting IL-22 production. <i>Phytomedicine</i> , 2018, 47, 48-57.	5.3	19
419	The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1682.	4.8	312
420	Tildrakizumab for the treatment of psoriasis. <i>Immunotherapy</i> , 2018, 10, 1105-1122.	2.0	7
421	Dermatitis atá pica del adulto: de la fisiopatología a la terapéutica (i). <i>Piel</i> , 2018, 33, 562-570.	0.0	0
423	Systemic and stratum corneum biomarkers of severity in infant atopic dermatitis include markers of innate and T helper cell-related immunity and angiogenesis. <i>British Journal of Dermatology</i> , 2019, 180, 586-596.	1.5	70
424	Targeting the gut-skin axis? Probiotics as new tools for skin disorder management?. <i>Experimental Dermatology</i> , 2019, 28, 1210-1218.	2.9	88
425	Interleukin-17A affects extracellular vesicles release and cargo in human keratinocytes. <i>Experimental Dermatology</i> , 2019, 28, 1066-1073.	2.9	8
426	Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1036-1049.	2.9	37
427	Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019, Volume 12, 509-517.	1.8	25
428	IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 750-763.	2.9	104

#	ARTICLE	IF	CITATIONS
429	Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis. Case Reports in Dermatology, 2019, 11, 1-3.	0.8	4
430	Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Seminars in Immunopathology, 2019, 41, 633-644.	6.1	41
431	Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. Case Reports in Dermatology, 2019, 11, 11-16.	0.8	5
432	Antagonistic Effects of IL-4 on IL-17A-Mediated Enhancement of Epidermal Tight Junction Function. International Journal of Molecular Sciences, 2019, 20, 4070.	4.1	23
433	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 1011-1024.	2.9	95
434	An update on generalized pustular psoriasis. Expert Review of Clinical Immunology, 2019, 15, 907-919.	3.0	122
435	Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models. Cells, 2019, 8, 1089.	4.1	48
436	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 370-380.	5.6	27
437	Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opinion on Biological Therapy, 2019, 19, 367-380.	3.1	19
438	The contribution of IL-17 to the development of autoimmunity in psoriasis. Innate Immunity, 2019, 25, 337-343.	2.4	17
439	CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by V β 4+ T cells. Journal of Autoimmunity, 2019, 101, 70-85.	6.5	8
440	Integrated analysis of gene expression profiles identifies transcription factors potentially involved in psoriasis pathogenesis. Journal of Cellular Biochemistry, 2019, 120, 12582-12594.	2.6	11
441	Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 144-156.	2.9	99
442	2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells. Frontiers in Immunology, 2019, 10, 589.	4.8	12
443	Mast cells in hidradenitis suppurativa: a clinicopathological study. Archives of Dermatological Research, 2019, 311, 331-335.	1.9	18
444	A20 and ABIN1 Suppression of a Keratinocyte Inflammatory Program with a Shared Single-Cell Expression Signature in Diverse Human Rashes. Journal of Investigative Dermatology, 2019, 139, 1264-1273.	0.7	16
445	What's New in Atopic Dermatitis. Dermatologic Clinics, 2019, 37, 205-213.	1.7	48
446	Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. Journal of the American Academy of Dermatology, 2019, 80, 714-721.	1.2	70

#	ARTICLE	IF	CITATIONS
447	Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis. <i>Cytokine and Growth Factor Reviews</i> , 2019, 45, 35-44.	7.2	49
448	Treating to Target(s) With Interleukin-17 Inhibitors. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 3S-34S.	1.2	6
449	Interleukin-17: Potential Target for Chronic Wounds. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	3.0	22
450	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 142-154.	2.9	135
451	Atopic dermatitis: a review of evolving targeted therapies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 275-288.	3.0	16
452	CD44 Assists the Topical Anti-Psoriatic Efficacy of Curcumin-Loaded Hyaluronan-Modified Ethosomes: A New Strategy for Clustering Drug in Inflammatory Skin. <i>Theranostics</i> , 2019, 9, 48-64.	10.0	127
453	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 155-172.	2.9	436
454	Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 174-177.	1.2	18
455	Ras homolog gene family H (RhoH) deficiency induces psoriasis-like chronic dermatitis by promoting TH17 cell polarization. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1878-1891.	2.9	14
456	A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1444-1454.	2.9	62
457	IL-22 Down-Regulates Cx43 Expression and Decreases Gap Junctional Intercellular Communication by Activating the JNK Pathway in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 400-411.	0.7	23
458	Computational Analysis Supports IL-17A as a Central Driver of Neutrophil Extracellular Trap-Mediated Injury in Liver Ischemia Reperfusion. <i>Journal of Immunology</i> , 2019, 202, 268-277.	0.8	25
459	Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 103-108.	2.3	26
460	Genomic alterations driving psoriasis pathogenesis. <i>Gene</i> , 2019, 683, 61-71.	2.2	50
461	Gut microbiome and bone. <i>Joint Bone Spine</i> , 2019, 86, 43-47.	1.6	63
462	New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 28-35.	1.0	102
463	Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1026-1034.	0.7	25
464	Review of treatments for generalized pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 492-494.	2.2	19

#	ARTICLE	IF	CITATIONS
465	IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art. International Journal of Dermatology, 2020, 59, 406-411.	1.0	37
466	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 119-128.	3.0	12
467	Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways. Biomedicine and Pharmacotherapy, 2020, 123, 109747.	5.6	30
468	Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. Journal of Allergy and Clinical Immunology, 2020, 145, 922-932.	2.9	40
469	Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and Î²-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor Î± inhibitor-associated dermatitis. Journal of the American Academy of Dermatology, 2020, 82, 430-439.	1.2	29
470	Pyrolytic oils from Amphipterygium adstringens bark inhibit IL-8 production of IL-17-stimulated HaCaT keratinocytes. Journal of Analytical and Applied Pyrolysis, 2020, 145, 104749.	5.5	8
471	Identification of candidate genes affecting chronic subclinical mastitis in Norwegian Red cattle: combining genome-wide association study, topologically associated domains and pathway enrichment analysis. Animal Genetics, 2020, 51, 22-31.	1.7	16
472	Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis. Journal of Dermatology, 2020, 47, 155-162.	1.2	4
473	Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. Dermatologic Therapy, 2020, 33, e14378.	1.7	5
474	Signaling networks in inflammatory pathways and risk for suicidal behavior. Brain, Behavior, & Immunity - Health, 2020, 7, 100122.	2.5	8
475	Effect of IFN-Î³ on the kynurenine/tryptophan ratio in monolayer-cultured keratinocytes and a 3D reconstructed human epidermis model. Journal of Dermatological Science, 2020, 99, 177-184.	1.9	8
476	Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. International Journal of Molecular Sciences, 2020, 21, 5382.	4.1	181
477	Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	219
478	EASI pEASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3287-3289.	5.7	16
479	The role of Langerhans cells in epidermal homeostasis and pathogenesis of psoriasis. Journal of Cellular and Molecular Medicine, 2020, 24, 11646-11655.	3.6	22
480	Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair. Science Immunology, 2020, 5, .	11.9	99
481	IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clinical and Experimental Immunology, 2020, 201, 121-134.	2.6	66
482	DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity. Tissue Barriers, 2020, 8, 1765633.	3.2	3

#	ARTICLE	IF	CITATIONS
483	Psoriatic arthritis under the influence of IFN γ . Clinical Immunology, 2020, 218, 108513.	3.2	10
484	Cutaneous barrier dysfunction in allergic diseases. Journal of Allergy and Clinical Immunology, 2020, 145, 1485-1497.	2.9	94
485	Interleukin-22 promotes the migration and invasion of oral squamous cell carcinoma cells. Immunological Medicine, 2020, 43, 121-129.	2.6	3
486	Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 626-636.	2.2	18
487	Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab. Journal of Dermatology, 2020, 47, 452-457.	1.2	8
488	Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Frontiers in Pharmacology, 2020, 11, 117.	3.5	80
489	Recapitulating T cell infiltration in 3D psoriatic skin models for patient-specific drug testing. Scientific Reports, 2020, 10, 4123.	3.3	31
490	Myeloid-Derived Suppressor Cell-Derived Arginase-1 Oppositely Modulates IL-17A and IL-17F Through the ESR/STAT3 Pathway During Colitis in Mice. Frontiers in Immunology, 2020, 11, 687.	4.8	16
491	The role of the interleukin γ 23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1695-1706.	2.4	57
492	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Frontiers in Immunology, 2019, 10, 3096.	4.8	122
493	Interleukin-17A and Keratinocytes in Psoriasis. International Journal of Molecular Sciences, 2020, 21, 1275.	4.1	134
494	S1PR4 γ -dependent CCL2 production promotes macrophage recruitment in a murine psoriasis model. European Journal of Immunology, 2020, 50, 839-845.	2.9	22
495	Role of Aryl Hydrocarbon Receptor Activation and Autophagy in Psoriasis-Related Inflammation. International Journal of Molecular Sciences, 2020, 21, 2195.	4.1	29
496	Tumor Necrosis Factor Inhibitors. , 2021, , 287-301.e7.		2
497	Interleukin 12/23 Inhibitors. , 2021, , 302-311.e2.		0
498	Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. Journal of Allergy and Clinical Immunology, 2021, 147, 199-212.	2.9	113
499	Emerging treatments for atopic dermatitis. Journal of Dermatology, 2021, 48, 152-157.	1.2	7
500	The attentive focus on T cell γ -mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. Scandinavian Journal of Immunology, 2021, 93, e13000.	2.7	20

#	ARTICLE	IF	CITATIONS
501	Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. American Journal of Clinical Dermatology, 2021, 22, 173-192.	6.7	79
502	Basics and recent advances in the pathophysiology of atopic dermatitis. Journal of Dermatology, 2021, 48, 130-139.	1.2	71
503	“Autoinflammatory psoriasis” genetics and biology of pustular psoriasis. Cellular and Molecular Immunology, 2021, 18, 307-317.	10.5	63
504	Innate Immune Mechanisms of Arterial Hypertension and Autoimmune Disease. American Journal of Hypertension, 2021, 34, 143-153.	2.0	4
505	Autoimmune diseases and apoptosis: Targets, challenges, and innovations. , 2021, , 285-327.		1
506	Cytokines in psoriasis. Advances in Clinical Chemistry, 2021, 100, 171-204.	3.7	45
507	Increase in primary cilia in the epidermis of patients with atopic dermatitis and psoriasis. Experimental Dermatology, 2021, 30, 792-803.	2.9	9
508	<i>Stratum corneum</i> markers of innate and T helper cell-related immunity and their relation to the disease severity in Croatian patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1186-1196.	2.4	5
509	Advances in the Application of Natural Products and the Novel Drug Delivery Systems for Psoriasis. Frontiers in Pharmacology, 2021, 12, 644952.	3.5	20
510	The Association of Psoriasis and Obesity: Focusing on IL-17A-Related Immunological Mechanisms. International Journal of Dermatology and Venereology, 2021, 4, 116-121.	0.3	8
511	Biotechnologically Produced Lavandula angustifolia Mill. Extract Rich in Rosmarinic Acid Resolves Psoriasis-Related Inflammation Through Janus Kinase/Signal Transducer and Activator of Transcription Signaling. Frontiers in Pharmacology, 2021, 12, 680168.	3.5	11
512	Interleukin-22 and keratinocytes; pathogenic implications in skin inflammation. , 0, , .		2
513	Immunological Aspects of Skin Aging in Atopic Dermatitis. International Journal of Molecular Sciences, 2021, 22, 5729.	4.1	20
514	Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Science Translational Medicine, 2021, 13, .	12.4	27
516	New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression. Journal of Clinical Medicine, 2021, 10, 2506.	2.4	18
517	T cell transgressions: Tales of T cell form and function in diverse disease states. International Reviews of Immunology, 2021, , 1-42.	3.3	3
518	High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. Journal of Allergy and Clinical Immunology, 2022, 149, 135-144.e12.	2.9	14
519	Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk. Frontiers in Immunology, 2021, 12, 688861.	4.8	7

#	ARTICLE	IF	CITATIONS
520	Vitamin D Inhibits IL-22 Production Through a Repressive Vitamin D Response Element in the <i>il22</i> Promoter. <i>Frontiers in Immunology</i> , 2021, 12, 715059.	4.8	9
521	The Role of T Lymphocytes in Cutaneous Scarring. <i>Advances in Wound Care</i> , 2022, 11, 121-131.	5.1	15
522	Skin-Resident Memory T Cells: Pathogenesis and Implication for the Treatment of Psoriasis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3822.	2.4	14
523	Impact of isoflavone genistein on psoriasis in in vivo and in vitro investigations. <i>Scientific Reports</i> , 2021, 11, 18297.	3.3	6
524	Tâ€cell subsets in the skin and their role in inflammatory skin disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 827-842.	5.7	27
525	Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2208-2218.e14.	0.7	54
526	Early intervention and prevention of allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 416-441.	5.7	44
528	CXCL10 and its related key genes as potential biomarkers for psoriasis. <i>Medicine (United States)</i> , 2021, 100, e27365.	1.0	7
529	Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17âcell axis. <i>Journal of Ethnopharmacology</i> , 2021, 281, 114571.	4.1	18
530	Psoriasis-like Inflammation Induced in an Air-pouch Mouse Model. <i>In Vivo</i> , 2021, 35, 1985-1997.	1.3	2
531	Neuro-dermatological association between psoriasis and depression: an immune-mediated inflammatory process validating skin-brain axis theory. <i>AIMS Neuroscience</i> , 2021, 8, 340-354.	2.3	8
533	TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency. <i>Scientific Reports</i> , 2020, 10, 734.	3.3	10
536	Epithelial barrier repair and prevention of allergy. <i>Journal of Clinical Investigation</i> , 2019, 129, 1463-1474.	8.2	137
537	GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. <i>Journal of Clinical Investigation</i> , 2020, 130, 5180-5196.	8.2	56
538	Understanding Therapeutic Pathways and Comorbidities in Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S20-S23.	1.6	5
539	Atopic dermatitis: pathogenesis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 100-103.	1.6	59
540	Atopic Dermatitis-Like Disease and Associated Lethal Myeloproliferative Disorder Arise from Loss of Notch Signaling in the Murine Skin. <i>PLoS ONE</i> , 2010, 5, e9258.	2.5	148
541	Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1Î². <i>PLoS ONE</i> , 2012, 7, e49408.	2.5	36

#	ARTICLE	IF	CITATIONS
542	CD57 Expression and Cytokine Production by T Cells in Lesional and Unaffected Skin from Patients with Psoriasis. PLoS ONE, 2013, 8, e52144.	2.5	10
543	Inhibition of Keratinocyte Differentiation by the Synergistic Effect of IL-17A, IL-22, IL-1 β , TNF α and Oncostatin M. PLoS ONE, 2014, 9, e101937.	2.5	105
544	CARD14 Expression in Dermal Endothelial Cells in Psoriasis. PLoS ONE, 2014, 9, e111255.	2.5	52
545	Vitamin D Regulates Cytokine Patterns Secreted by Dendritic Cells to Promote Differentiation of IL-22-Producing T Cells. PLoS ONE, 2015, 10, e0130395.	2.5	46
546	The pathogenic role of interleukin-22 and its receptor during UVB-induced skin inflammation. PLoS ONE, 2017, 12, e0178567.	2.5	19
547	Interleukin-17A pathway target genes are upregulated in Equus caballus supporting limb laminitis. PLoS ONE, 2020, 15, e0232920.	2.5	6
548	Immunological Mechanisms of Neuropsychiatric Lupus. Current Immunology Reviews, 2015, 11, 93-106.	1.2	1
549	Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms. The Open Biochemistry Journal, 2014, 8, 21-34.	0.5	17
550	Psoriasis and the TNF/IL23/IL17 axis. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 418-424.	0.8	50
551	Evaluation of hearing in patients with psoriasis considering the disease severity. Ent Updates, 2016, 6, 140-144.	0.2	4
552	Skin "a vast organ with immunological function (Review). Experimental and Therapeutic Medicine, 2020, 20, 18-23.	1.8	15
553	IL-22: There Is a Gap in Our Knowledge. ImmunoHorizons, 2018, 2, 198-207.	1.8	77
554	IL-17 Expression Requires Both TYK2/STAT3 Activity and IL-17-Regulated mRNA Stabilization. ImmunoHorizons, 2019, 3, 172-185.	1.8	17
555	Biological therapy of psoriasis. Indian Journal of Dermatology, 2010, 55, 161.	0.3	36
556	In-Depth, Proteomic Analysis of Nasal Secretions from Patients With Chronic Rhinosinusitis and Nasal Polyps. Allergy, Asthma and Immunology Research, 2019, 11, 691.	2.9	24
557	Interleukin-17 and Interleukin-22 Induced Proinflammatory Cytokine Production in Keratinocytes via Inhibitor of Nuclear Factor κ B Kinase-1 α Expression. Annals of Dermatology, 2012, 24, 398.	0.9	23
558	Novel key cytokines in allergy: IL-17, IL-22. Allergologie Select, 2017, 1, 71-76.	3.1	4
559	Avoiding contact allergens: from basic research to the in vitro identification of contact allergens. Allergologie Select, 2017, 1, 77-84.	3.1	3

#	ARTICLE	IF	CITATIONS
560	Expression and Function of CCL17 in Atopic Dermatitis. , 0, , .		1
561	In Vitro Models Mimicking Immune Response in the Skin. Yonsei Medical Journal, 2021, 62, 969.	2.2	24
562	Skin Barrier Dysregulation in Psoriasis. International Journal of Molecular Sciences, 2021, 22, 10841.	4.1	57
563	First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis. Scientific Reports, 2021, 11, 19827.	3.3	6
564	Insights into the Pathogenesis and Treatment of Psoriasis. , 0, , .		0
565	Use of Microarray Technology to Improve DNA Vaccines in Fish Aquaculture - The Rhabdoviral Model. , 0, , .		0
566	Contribution of IL-22 to Experimental Skin Inflammation. , 2013, , 305-317.		0
568	Yeni Tanımlanmış Bir T H ₁ /4cre Alt Tipi: Th22 ve Cilt Hastalıkları. Turk Dermatoloji Dergisi, 2014, 8, 35-38.		0
569	The Adaptive Immunity. , 2017, , 27-37.		0
571	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
572	Biologic Therapies for Psoriasis. , 2017, , 757-765.		0
573	Papulosquamous Diseases. , 2017, , 23-59.		0
574	Case Studies. Advances in Experimental Medicine and Biology, 2018, 1069, 135-209.	1.6	0
575	Expression and significance of interleukin-17 and interleukin-22 in the serum and the lower esophageal sphincter of patients with achalasia. Saudi Journal of Gastroenterology, 2018, 24, 242.	1.1	6
576	Innovative domestic product - a new era of psoriasis therapy. Klinicheskaya Dermatologiya i Venerologiya, 2019, 18, 479.	0.2	0
577	Inflammation of the Skin and Its Therapeutic Targets. , 2020, , 141-174.		1
578	Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment. Medical Science Monitor, 2020, 26, e920371.	1.1	3
579	Biomimetic Scaffolds Modulate the Posttraumatic Inflammatory Response in Articular Cartilage Contributing to Enhanced Neoformation of Cartilaginous Tissue In Vivo. Advanced Healthcare Materials, 2022, 11, e2101127.	7.6	13

#	ARTICLE	IF	CITATIONS
582	Basophil-derived IL-4 promotes cutaneous Staphylococcus aureus infection. JCI Insight, 2021, 6, .	5.0	15
584	Glycyrrhizin combined with acitretin improve clinical symptom of psoriasis via reducing Th17 cell differentiation and related serum cytokine concentrations. International Journal of Clinical and Experimental Medicine, 2015, 8, 16266-72.	1.3	11
585	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting. Journal of Clinical and Aesthetic Dermatology, 2017, 10, S8-S41.	0.1	2
586	Leucosceptoside A from Devilâ€™s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes. Molecules, 2021, 26, 7014.	3.8	5
587	IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology. Frontiers in Immunology, 2021, 12, 766586.	4.8	22
589	Prevalence of <i>Candida species</i> in Psoriasis. Mycoses, 2022, 65, 247-254.	4.0	4
590	Gut and Cutaneous Microbiome Featuring Abundance of Lactobacillus reuteri Protected Against Psoriasis-Like Inflammation in Mice. Journal of Inflammation Research, 2021, Volume 14, 6175-6190.	3.5	7
591	Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. Journal of Allergy and Clinical Immunology, 2022, 149, 2010-2020.e8.	2.9	37
592	Logical and experimental modeling of cytokine and eicosanoid signaling in psoriatic keratinocytes. IScience, 2021, 24, 103451.	4.1	7
593	Genetic variants in IL-17A rs10484879 and serum levels of IL-17A are associated with psoriasis risk. Archives of Dermatological Research, 2021, , 1.	1.9	3
594	Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study. BMC Pulmonary Medicine, 2021, 21, 393.	2.0	12
595	RegEnrich gene regulator enrichment analysis reveals a key role of the ETS transcription factor family in interferon signaling. Communications Biology, 2022, 5, 31.	4.4	7
596	Association of IL-17A gene polymorphism rs2275913 with the polycystic ovary syndrome in Yunnan Province, China. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 271, 27-30.	1.1	2
597	Role of Th17 Cytokines in Airway Remodeling in Asthma and Therapy Perspectives. Frontiers in Allergy, 2022, 3, 806391.	2.8	8
598	On the efficiency and safety of application of the short course of clobetasol propionate at patients, suffering from psoriasis in the progression phase. Vestnik Dermatologii I Venerologii, 2012, 88, 121-125.	0.6	0
599	Antigen-Presenting Cells in Psoriasis. Life, 2022, 12, 234.	2.4	6
600	Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 1767.	4.1	8
601	In Vitro Disease Models for Understanding Psoriasis and Atopic Dermatitis. Frontiers in Bioengineering and Biotechnology, 2022, 10, 803218.	4.1	13

#	ARTICLE	IF	CITATIONS
602	Cytokine induced 3â€D organotypic psoriasis skin model demonstrates distinct roles for NFâ€B and JAK pathways in disease pathophysiology. Experimental Dermatology, 2022, 31, 1036-1047.	2.9	6
603	Bioinspired Rotation Microneedles for Accurate Transdermal Positioning and Ultraminimal-Invasive Biomarker Detection with Mechanical Robustness. Research, 2022, 2022, 9869734.	5.7	8
604	Cytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis. Frontiers in Immunology, 2022, 13, 801579.	4.8	23
605	The Role of Helper T Cells in Psoriasis. Frontiers in Immunology, 2021, 12, 788940.	4.8	70
606	Anti-Psoriatic Effects and IL-22 Targeting Mechanism of Indirubin by Suppressing Keratinocyte Inflammation and Proliferation. Applied Sciences (Switzerland), 2021, 11, 11599.	2.5	2
607	Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. Journal of Investigative Dermatology, 2022, 142, 2363-2374.e18.	0.7	11
608	Assessment of some immune markers in typhoid-patients. International Journal of Health Sciences, 0, , 4199-4210.	0.1	0
609	Immunomodulatory Effect of Methotrexate Abruptly Controls Keratinocyte Activation in Psoriasis. , 0, , .		1
617	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. Science Advances, 2022, 8, eabn4776.	10.3	15
618	Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders. Psoriasis: Targets and Therapy, 2022, Volume 12, 73-87.	2.2	20
619	Keratinocyte <scp>EGF</scp> signaling dominates in Atopic Dermatitis lesions: a comparative <scp>RNAseq</scp> analysis. Experimental Dermatology, 2022, , .	2.9	2
620	Tumor necrosis factor (TNF) inhibitors. , 2013, , 307-318.e4.		1
621	Interleukin 12/23 inhibitors. , 2013, , 319-332.e2.		0
622	Transcriptional Basis of Psoriasis from Large Scale Gene Expression Studies: The Importance of Moving towards a Precision Medicine Approach. International Journal of Molecular Sciences, 2022, 23, 6130.	4.1	8
623	Emerging Targeted Treatments. , 2023, , 237-251.		1
624	Asian type atopic dermatitis. , 0, 2, 48.		0
625	Recurrence of Relapsing Polychondritis on Tumor Necrosis Factor Antagonist Cessation and Starting an Interleukin-17 A Inhibitor. Medical Journal of Southern California Clinicians, 2022, , 8-11.	0.2	0
626	The Effect of the Long-Term Calcipotriol/Betamethasone Dipropionate Local Therapy on Tissue Resident Memory Cells Markers in Psoriatic Eruptions. International Journal of Environmental Research and Public Health, 2022, 19, 8345.	2.6	2

#	ARTICLE	IF	CITATIONS
627	Single-cell transcriptomics reveals a senescence-associated <sc>IL</sc> - <sc>CCR6</sc> axis driving radiodermatitis. EMBO Molecular Medicine, 2022, 14, .	6.9	9
628	The Role of T Helper 22 Cells in Dermatological Disorders. Frontiers in Immunology, 0, 13, .	4.8	8
629	p38 MAPK Inhibitor NJK14047 Suppresses CDNB-Induced Atopic Dermatitis-Like Symptoms in BALB/c Mice. Biomolecules and Therapeutics, 2022, 30, 501-509.	2.4	5
630	Identification of Effective Diagnostic Biomarkers and Immune Cell Infiltration in Atopic Dermatitis by Comprehensive Bioinformatics Analysis. Frontiers in Molecular Biosciences, 0, 9, .	3.5	2
631	Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice. Nature Communications, 2022, 13, .	12.8	19
632	Exposing the Two Contrasting Faces of STAT2 in Inflammation. Journal of Interferon and Cytokine Research, 2022, 42, 467-481.	1.2	3
633	A sharp decrease of Th17, CXCR3+Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis. Clinical and Experimental Immunology, 2022, 210, 79-89.	2.6	4
634	The family of kallikrein-related peptidases and kinin peptides as modulators of epidermal homeostasis. American Journal of Physiology - Cell Physiology, 0, , .	4.6	4
635	Expression of B lymphocyte-induced maturation protein 1 (Blimp-1) in keratinocyte and cytokine signalling drives human Th17 response in psoriasis. Archives of Dermatological Research, 2023, 315, 481-490.	1.9	1
636	Individualised computational modelling of immune mediated disease onset, flare and clearance in psoriasis. PLoS Computational Biology, 2022, 18, e1010267.	3.2	2
637	ARG1 and CXCL2 are potential biomarkers target for psoriasis patients. Molecular Pain, 2022, 18, 174480692211284.	2.1	1
638	Impact of ROS-Dependent Lipid Metabolism on Psoriasis Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 12137.	4.1	10
639	Keratinocyte-induced costimulation of human T cells through CD6 - but not CD2 - activates mTOR and prevents oxidative stress. Frontiers in Immunology, 0, 13, .	4.8	0
640	Alliin ameliorates imiquimod-induced psoriasis-like skin inflammation via disturbing the interaction of keratinocytes with IL-17A. British Journal of Pharmacology, 2023, 180, 628-646.	5.4	5
642	The role of heterodimer IL 17A/F in atopic dermatitis. Postepy Dermatologii I Alergologii, 2022, 39, 1093-1100.	0.9	4
643	IL-17A and TNF-Î± inhibitors induce multiple molecular changes in psoriasis. Frontiers in Immunology, 0, 13, .	4.8	3
644	The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin. International Journal of Molecular Sciences, 2023, 24, 205.	4.1	8
645	Aruncus dioicus var. kamtschaticus Extract Ameliorates Psoriasis-like Skin Inflammation via Akt/mTOR and JAK2/STAT3 Signaling Pathways in a Murine Model. Nutrients, 2022, 14, 5094.	4.1	4

#	ARTICLE	IF	CITATIONS
646	Induction of psoriasis- and atopic dermatitis-like phenotypes in 3D skin equivalents with a fibroblast-derived matrix. Scientific Reports, 2023, 13, .	3.3	5
647	The evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective. Clinical and Experimental Allergy, 2023, 53, 156-172.	2.9	12
648	Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Seminars in Arthritis and Rheumatism, 2023, 59, 152165.	3.4	3
649	Barrier functionâ€related genes and proteins have an altered expression in acneâ€involved skin. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1415-1425.	2.4	3
652	The therapeutic effect of tacrolimus in a mouse psoriatic model is associated with the induction of myeloid-derived suppressor cells. Rheumatology and Immunology Research, 2022, 3, 190-197.	0.8	1
653	Inflammatory Cytokines Associated with Multiple Sclerosis Directly Induce Alterations of Neuronal Cytoarchitecture in Human Neurons. Journal of NeuroImmune Pharmacology, 2023, 18, 145-159.	4.1	3
654	Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences, 2023, 24, 4901.	4.1	15
655	Association between psoriasis, sleep, and dermatological quality of life: results of a cross-sectional study. Italian Journal of Dermatology and Venereology, 2023, 158, .	0.2	0
656	Transcriptional regulation on effector T cells in the pathogenesis of psoriasis. European Journal of Medical Research, 2023, 28, .	2.2	1
657	IL-22 as a target for therapeutic intervention: Current knowledge on its role in various diseases. Cytokine, 2023, 169, 156293.	3.2	2
658	Update on the role of cytokines and chemokines in canine atopic dermatitis. Veterinary Dermatology, 2024, 35, 25-39.	1.2	2
659	DNA methylation patterns in CD4+ T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis. Frontiers in Immunology, 0, 14, .	4.8	2
660	Rehmannioside A Inhibits TRAF6/MAPK Pathway and Improves Psoriasis by Interfering with the Interaction of HaCaT Cells with IL-17A. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 16, 2585-2596.	1.8	4
661	Site-Specifically Launched Microneedles for the Combined Treatment of Psoriasis-Diabetic Comorbidity. ACS Applied Materials & Interfaces, 2023, 15, 46613-46625.	8.0	1
662	The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity. Inflammation, 0, , .	3.8	1
663	Crosstalk: keratinocytes and immune cells in psoriasis. Frontiers in Immunology, 0, 14, .	4.8	2
664	Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic. Dermatology and Therapy, 0, , .	3.0	0
665	Roles of tumor necrosis factor-like ligand 1A in Î³T-cell activation and psoriasis pathogenesis. Frontiers in Immunology, 0, 15, .	4.8	0

#	ARTICLE	IF	CITATIONS
666	From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature. Frontiers in Medicine, 0, 11, .	2.6	0